Sherif Al-Farra, MD
Pulmonary Disease · Fort Worth, TXNPI 1093770737
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,780 of the $12,635 with a category attached, or 77.4%. Sunovion Pharmaceuticals Inc. accounts for 81.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $10,600 and has fallen 96.7% since, to $350 in 2023.
Across 42 payments — averaging $300.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$10K
- AstraZeneca$2K
- Insmed, Inc.$52
- Advanced Respiratory, Inc$40
- Philips North America LLC$30
- Boehringer Ingelheim$27
- plus $63 from 4 others
Across 21 payments — averaging $20,470 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$430K
What the payments were for
- Consulting fees$1,68513%
- Speaking & faculty fees$9,78077%
- Travel & lodging$5254%
- Food & beverage$6455%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 18 | $10,341 |
| AstraZeneca | 12 | $2,082 |
| Insmed, Inc. | 3 | $52 |
| Advanced Respiratory, Inc | 2 | $40 |
| Philips North America LLC | 2 | $30 |
| Boehringer Ingelheim | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Merck | 1 | $12 |
| GSK | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LONHALA MAGNAIR$10,032
- FASENRA$1,685
How this compares
$12,635 in reported general payments places this provider in the 80th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $347,795 |
| Spiriva HandihalerTiotropium Bromide | 82 | $82,311 |
| SymbicortBudesonide/Formoterol Fumarate | 115 | $51,921 |
| Incruse ElliptaUmeclidinium Bromide | 49 | $40,115 |
| Spiriva RespimatTiotropium Bromide | 28 | $29,253 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $21,550 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $17,417 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $17,015 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 39 | $11,363 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 39 | $10,800 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 168 | $8,786 |
| Advair DiskusFluticasone Propion/Salmeterol | 14 | $8,722 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $4,722 |
| Roflumilast | 12 | $3,958 |
| Wixela InhubFluticasone Propion/Salmeterol | 33 | $3,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $27 | $377,04753 claims |
| GSKIncruse Ellipta, Trelegy Ellipta, Breo Ellipta | $11 | $79,08294 claims |
| AstraZenecaSymbicort | $2,082 | $51,921115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Fort Worth
- Steven KimFort Worth$160K
- Andrew MillerFort Worth$112K
- David OstranskyFort Worth$107K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.